Oury Medical, an independent French industrial group specialising in the manufacture of medical instrumentation, has acquired Céfiméca, a manufacturer of orthopaedic and spinal instruments and implants.
The transaction represents another step in the long-term industrial strategy initiated by TAG Partners at the time of its acquisition of Oury-Guyé three years ago.
Since the founding acquisition, TAG Partners – an independent investment firm supporting high-potential French SMEs in ownership transition, transformation and growth – which acquired a majority share in the firm alongside Tioopo Capital has actively supported the group’s transformation, resulting in c.20% annual growth and a series of targeted acquisitions.
“When we acquired Oury-Guyé three years ago, our ambition was clear: to build a leading French industrial platform in orthopaedic and spinal medical instrumentation through a disciplined build-up strategy,” said Georges-Alexandre Ancenys, Thierry Manceau and André Wagner, founding partners of TAG Partners. “Since then, we have completed five acquisitions to progressively assemble complementary know-how. The acquisition of Céfiméca [the fifth acquisition] fully fits within this vision and further strengthens Oury Medical’s positioning as a strategic partner for our orthopaedic clients with a One-Stop-Shop offering.”
Oury Medical has five production sites in France and a workforce of over 200.
Founded in 1992, Céfiméca has specialised in the manufacture of surgical instruments and orthopaedic implants. In 2023, Céfiméca had 125 employees and a turnover of €13.3m.
“Joining Oury Medical allows us to leverage complementary capabilities and to continue our development within a broader and more ambitious industrial platform,” said Frédéric Mazenod, chairman of Céfiméca.
The acquisition is financed by TAG Partners and ISALT, an independent French asset management company, alongside several family offices and private investors. It sees Tioopo make its first exit. Tioopo reports the investment made a 29.2% IRR, more than 2x net for its investors during the hold period.
This new financing round aims both to finance the acquisition of Céfiméca and to strengthen the group’s balance sheet, enabling the continuation of investments in technology, industrial capacities and growth.
“By integrating complementary capabilities in instrumentation and focused and high-value range of implants, we further strengthen the value we bring to our clients, while remaining focused on our industrial DNA,” said Sébastien Meunier, CEO of Oury Medical.
Press release: ourymedical.com/en/news/acquisition-cefimeca
